Cargando…

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial

Detalles Bibliográficos
Autores principales:	Pettitt, Andrew R., Jackson, Richard, Cicconi, Silvia, Polydoros, Fotis, Yap, Christina, Dodd, James, Bickerstaff, Matthew, Stackpoole, Michael, Khan, Umair T., Carruthers, Stacey, Oates, Melanie, Lin, Ke, Coupland, Sarah E., Menon, Geetha, Kalakonda, Nagesh, McCarthy, Helen, Bloor, Adrian, Schuh, Anna, Duncombe, Andrew, Dearden, Claire, Fegan, Christopher, Kennedy, Ben, Walewska, Renata, Marshall, Scott, Fox, Christopher P., Hillmen, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716354/ https://www.ncbi.nlm.nih.gov/pubmed/33256390 http://dx.doi.org/10.3324/haematol.2019.230805

Ejemplares similares

Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome
por: Eyre, Toby A, et al.
Publicado: (2015)

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial
por: Howard, Dena R., et al.
Publicado: (2016)

Cancer Informatics in the U.K.: The NCRI Informatics Initiative
por: Reddington, Fiona, et al.
Publicado: (2007)

Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells
por: Linley, Adam J., et al.
Publicado: (2021)

Impfungen unter Ofatumumab gelingen
por: Facharztmagazine, Redaktion
Publicado: (2023)

Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
por: Barrientos, Jacqueline C., et al.
Publicado: (2018)

An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects
por: Alharthi, Afaf, et al.
Publicado: (2018)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Ofatumumab treatment in lupus nephritis patients
por: Haarhaus, Malena Loberg, et al.
Publicado: (2016)

COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis
por: Lim, Yeong Jer, et al.
Publicado: (2022)

Role of ofatumumab in treatment of chronic lymphocytic leukemia
por: Veliz, Marays, et al.
Publicado: (2011)

Refractory pemphigus vulgaris successfully treated with ofatumumab
por: Klufas, Daniel M., et al.
Publicado: (2020)

Selected Abstracts from the 2018 NCRI Cancer Conference of National Cancer Research Institute
Publicado: (2018)

Selected Abstracts from the 2019 NCRI Cancer Conference of National Cancer Research Institute
Publicado: (2019)

The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
por: Nabhan, Chadi, et al.
Publicado: (2011)

Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Nutzen der frühzeitigen Behandlung mit Ofatumumab bestätigt
por: Linder, Isabelle
Publicado: (2022)

ncRI: a manually curated database for experimentally validated non-coding RNAs in inflammation
por: Wang, Shuyuan, et al.
Publicado: (2020)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Alemtuzumab in Covid era
por: Iovino, Aniello, et al.
Publicado: (2021)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Telomere length predicts for outcome to FCR chemotherapy in CLL
por: Norris, Kevin, et al.
Publicado: (2019)

Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010)

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab
por: Laurenti, Luca, et al.
Publicado: (2016)

Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling
por: Payandeh, Zahra, et al.
Publicado: (2018)

Ofatumumab‐associated acute pneumonitis: Not new but still the first case
por: Bonanni, Alice, et al.
Publicado: (2016)

Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Tuscano, Joseph, et al.
Publicado: (2020)

Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Nutzen der frühzeitigen MS-Behandlung mit Ofatumumab bestätigt
por: Linder, Isabelle
Publicado: (2022)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey, Divyanshu, et al.
Publicado: (2015)

ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)
por: Banerjee, Susana, et al.
Publicado: (2021)

Alemtuzumab in the up-front setting
por: Kaufman, Matthew, et al.
Publicado: (2008)

Alemtuzumab in chronic lymphocytic leukemia
por: Fraser, G., et al.
Publicado: (2007)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Alemtuzumab in refractory Sézary syndrome
por: Reifs, Carmen María Alcántara, et al.
Publicado: (2016)

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
por: Freeman, Sylvie D., et al.
Publicado: (2023)

The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies
por: Castillo, Jorge, et al.
Publicado: (2010)

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
por: Frustaci, Anna Maria, et al.
Publicado: (2015)

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
por: Bar-Or, Amit, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_eu7o9emre1e3j45bs46lknd7g1